- Home
- ELDN vs NTHI Comparison
ELDN vs NTHI Comparison
Compare ELDN & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELDN | NTHI |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.6M | 243.9M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELDN | NTHI |
|---|---|---|
| Price | $2.91 | $7.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 28.1K |
| Earning Date | 03-19-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $3.20 |
| 52 Week High | $4.60 | $16.00 |
Technical Indicators
Market Signals| Indicator | ELDN | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 61.99 | 32.21 |
| Support Level | $2.48 | $6.40 |
| Resistance Level | $3.21 | $7.70 |
| Average True Range (ATR) | 0.22 | 0.73 |
| MACD | 0.00 | -0.22 |
| Stochastic Oscillator | 66.44 | 1.66 |
Price Performance
Historical ComparisonAbout ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).